IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional images of lumen, it does not allow complete visualization of vascular structures. This can hinder appropriate selection of device size, balloon or stent, as well as the accurate assessment of procedural outcomes.

Intravascular ultrasound (IVUS) provides detailed information on vessel dimension and plaque characteristics. Its use has been shown to improve clinical outcomes in the treatment of complex coronary lesions. In recent years, IVUS has been increasingly used in peripheral artery disease; however, supporting clinical evidence vs standard angiography in peripheral artery interventions remains limited.

This prospective, multicenter, randomized study aimed to evaluate the outcomes of IVUS-guided vs angiography-guided treatment of femoropopliteal lesions with different levels of lesion complexity.

The primary endpoint was target lesion primary patency, defined as absence of clinically driven target lesion revascularization (CD-TLR) or restenosis at 12 months. The secondary endpoint included CD-TLR as well as clinical and hemodynamic improvement parameters.

A total of 237 patients undergoing drug-coated balloon angioplasty for femoropopliteal lesions were included in the IVUS-DCB study; 158 had complex lesions (TASC II type C/D) and 79 had non-complex lesions (TASC II type A/B).

Read also: QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis.

In complex lesions, IVUS use was associated with significantly higher primary patency (82.1% vs. 60.3%; HR: 0.34; 95% CI: 0.16-0.70; p = 0.002), lower incidence of CD-TLR (90.0% vs. 76.9%; HR: 0.31; 95% CI: 0.13-0.75; p = 0.01), and sustained clinical and hemodynamic improvement vs angiography guided angioplasty.

As regards non-complex lesions, no significant differences were observed in primary patency (87.5% vs. 88.2%; HR: 1.84; 95% CI: 0.39-8.60; p = 0.44) or incidence of secondary evaluation criteria between IVUS and angiography-guided balloon angioplasty.

Conclusion

 IVUS-guided drug coated balloon angioplasty was associated with higher primary patency rate and clinical improvement vs. the angiography-guided in the treatment of complex femoropopliteal lesions. In contrast, non-complex lesions showed no significant differences between these methods. 

Original Title: Intravascular Ultrasound-Guided vs Angiography-Guided Drug-Coated Balloon Angioplasty in Patients With Complex Femoropopliteal Artery Disease.

Reference: Seung-Jun Lee, MD et al JACC Cardiovasc Interv. 2025;18:558–569.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

 

Dr. Andrés Rodríguez
Dr. Andrés Rodríguez
Member of the Editorial Board of solaci.org

Más artículos de este Autor

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Chronic limb-threatening ischemia in patients without conventional revascularization options represents one of the most challenging scenarios within peripheral arterial disease, with 1-year major amputation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Artículos relacionados

Jornadas SOLACIspot_img

Artículos recientes

ACC 2026: SURViV Trial Results – Exclusive Presentation and Analysis with Dr. Dimytri Siqueira

Following the presentation of the SURViV trial in the Late Breaking Clinical Trials sessions at the American College of Cardiology Congress, Dr. Dimytri Siqueira...

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...